Power calculation for analysis 1
| Frequency of exposure to JAKis in the targeted cohort | OR | Nominal power | Controls (n) | Cases (n) | Participants (total n) |
| 0.50 | 1.5 | 0.8 | 1275 | 255 | 1530 |
| 0.50 | 2.0 | 0.8 | 465 | 93 | 558 |
| 0.50 | 3.0 | 0.8 | 205 | 41 | 246 |
| 0.25 | 1.5 | 0.8 | 1530 | 306 | 1836 |
| 0.25 | 2.0 | 0.8 | 515 | 103 | 618 |
| 0.25 | 2.5 | 0.8 | 295 | 59 | 354 |
| 0.25 | 3.0 | 0.8 | 205 | 41 | 246 |
| 0.25 | 3.5 | 0.8 | 160 | 32 | 192 |
JAKi, Janus kinase inhibitor.